Health Authorities: "No Contamination Risk in Janssen Vaccine Introduced Domestically"

[Image source=Reuters Yonhap News]

[Asia Economy Reporter Park Jihwan] The health authorities have stated that none of the Janssen vaccines imported into Korea, which are being administered to reservists and civil defense personnel aged 30 and above, were produced at the Baltimore factory in the United States where an accident occurred during the manufacturing process.

The Central Disaster and Safety Countermeasures Headquarters (CDSCH) of the Ministry of Health and Welfare announced on the 12th, "Among the 1.01 million doses of Janssen vaccine donated from the United States, none were produced at the Baltimore factory." The CDSCH added, "The imported quantity is assessed to have no contamination risk," and "Upon import, the Korea Food and Drug Administration (KFDA) conducted quality inspections and confirmed the vaccines were suitable." The KFDA conducted quality tests on 100 doses of the Janssen vaccine imported into Korea.

According to a report by The New York Times (NYT) the previous day, the U.S. Food and Drug Administration (FDA) decided to discard 6,000 doses of Janssen vaccine produced at the Baltimore factory where an accident occurred during COVID-19 vaccine manufacturing.

In March, at the Baltimore factory of Emergent BioSolutions, a manufacturing partner of Janssen vaccine, an incident occurred where components were mixed while simultaneously producing the viral vector vaccines Janssen and AstraZeneca-Oxford University's COVID-19 vaccine. As a result, 15 million doses of AstraZeneca were discarded.

This content was produced with the assistance of AI translation services.